Duchenne muscular dystrophy: Five trials to watch
The beginning to the year has been eventful in the Duchenne muscular dystrophy (DMD) space, with several trial readouts announced …
The beginning to the year has been eventful in the Duchenne muscular dystrophy (DMD) space, with several trial readouts announced …
Ensuring the integrity of pharmaceutical products is one of the most complex challenges in global healthcare today. From temperature-sensitive biologics …
US-based biopharmaceutical company KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat, an oral plasma kallikrein inhibitor …
Axsome Therapeutics’ Phase III Focus trial investigating its attention-deficit hyperactivity disorder (ADHD) therapy, Sunosi (solriamfetol), has met its primary endpoint …
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show …
Biotechnology company Tiziana Life Sciences has begun dosing subjects in its placebo-controlled Phase II trial of foralumab, an intranasal fully …
US-based biopharmaceutical company Helicore Biopharma has dosed the first subject in a randomised, first-in-human Phase I trial of its humanised …
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate …
Mural Oncology is discontinuing the development of nemvaleukin alfa in ovarian cancer after a Phase III trial failed to improve …
We’ve all seen the statistics – over 7,000 rare diseases, and only 5% have any approved treatments. It’s a situation …
Entrada Therapeutics has secured authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to …
Ractigen’s small activating RNA (saRNA) therapy, RAG-01, designed to treat non-muscle invasive bladder cancer (NMIBC) has shown early promise in …
Unity Biotechnology has reported topline outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic macular oedema. The …
Surrozen is dropping its sole clinical asset after the drug failed at Phase I, as the company considers a move …
Imunon has announced the alignment of the US Food and Drug Administration (FDA) with the Phase III OVATION 3 trial …